Drug Trial Radar · NCT00527683
Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
Last checked: Nov 19, 2026Latest source record: Apr 11, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Apr 2007
Primary completion
Nov 2007
Study completion Nov 2007
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Catalyst Pharmaceuticals, Inc.
- First posted
- Sep 11, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the efficacy of vigabatrin for the treatment of cocaine dependence, based on the twice-weekly qualitative urine toxicologies for cocaine. Based on two prior unblinded human studies and 15 years of animal studies, this 100 subject double- blind, randomized study is designed to show if with vigabatrin treatment but not placebo, even non-hospitalized cocaine dependent individuals with ready access to cocaine will become cocaine abstinent if they are self motivated to stop their cocaine habit. To accomplish this, cocaine dependent subjects will be randomly assigned to either a placebo or vigabatrin treatment group and treated for a nine week period. The primary hypothesis is that as compared to the placebo arm, the vigabatrin treatment arm will show a significant increase in the number of subjects who are abstinent for the final 3 weeks of the study.
Conditions
- Cocaine Dependence
Interventions
VigabatrinDrug
crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
PlaceboDrug
orange juice is administered twice daily in containers indistinguishable from the treatment arm.
Group therapyBehavioral
Participants attend group sessions once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Three consecutive weeks of negative urine tests (benzoyl ecgonine) for cocaine use (no slips allowed).Time frame: These must be the last three weeks (7,8,9) of the trial.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinica Integral de Tratamiento Contra las Adicciones SA de CV
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.